LAG-3: from molecular functions to clinical applications
To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points. Inhibitory coreceptors, including programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), ser...
Saved in:
| Main Authors: | Takumi Maruhashi, Daisuke Sugiura, Il-mi Okazaki, Taku Okazaki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001014.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Photoluminescence and scintillation properties of rare earth doped Lu2O3 single crystal grown by floating zone method
by: Takayuki Yanagida, et al.
Published: (2024-12-01) -
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
P013: Advances in multi-omics diagnostics studies of mitochondrial diseases in Japan
by: Yasushi Okazaki, et al.
Published: (2025-01-01) -
Therapeutic potential of targeting LAG-3 in cancer
by: Diwakar Davar, et al.
Published: (2025-07-01) -
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma
by: Melanie Wiecken, et al.
Published: (2025-12-01)